Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients

Jignesh K Patel, Guillaume Coutance, Alexandre Loupy, Deanna Dilibero, Michele Hamilton, Michelle Kittleson, Evan Kransdorf, Babak Azarbal, Osamu Seguchi, Xiaohai Zhang, David Chang, Dael Geft, Lawrence Czer, Shaida Varnous, Jon A Kobashigawa, Jignesh K Patel, Guillaume Coutance, Alexandre Loupy, Deanna Dilibero, Michele Hamilton, Michelle Kittleson, Evan Kransdorf, Babak Azarbal, Osamu Seguchi, Xiaohai Zhang, David Chang, Dael Geft, Lawrence Czer, Shaida Varnous, Jon A Kobashigawa

Abstract

Allosensitization represents a major barrier to heart transplantation (HTx). We assessed the efficacy and safety of complement inhibition at transplant in highly sensitized heart transplant recipients. We performed a single-center, single-arm, open-label trial (NCT02013037). Patients with panel reactive antibodies (PRA) ≥70% and pre-formed donor-specific antibodies (DSA) were eligible. In addition to standard of care, patients received nine infusions of eculizumab during the first 2 months posttransplant. The primary composite endpoint was antibody-mediated rejection (AMR) ≥pAMR2 and/or left ventricular dysfunction during the first year. Secondary endpoints included hemodynamic compromise, allograft rejection, and patient survival. Twenty patients were included. Median cPRA and mean fluorescence intensity of immunodominant DSA were 95% (90%-97%) and 6250 (5000-10 000), respectively. Retrospective B cell and T cell flow crossmatches were positive in 14 and 11 patients, respectively. The primary endpoint occurred in four patients (20%). Survival at 1 year was 90% with no deaths resulting from AMR. In a prespecified analysis comparing treated patients to matched control patients, we observed a dramatic reduction in the risk of biopsy-proven AMR in patients treated with eculizumab (HR = 0.36, 95% CI = 0.14-0.95, p = .032). Our findings support the prophylactic use of complement inhibition for heart transplantation at high immunological risk. ClinincalTrials.gov, NCT02013037.

Keywords: clinical research/practice; clinical trial; heart (allograft) function/dysfunction; heart transplantation/cardiology; immunosuppressant - fusion proteins and monoclonal antibodies; immunosuppression/immune modulation; rejection: antibody-mediated (ABMR); sensitization.

© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

References

REFERENCES

    1. Kobashigawa J, Colvin M, Potena L, et al. The management of antibodies in heart transplantation: an ISHLT consensus document. J Heart Lung Transplant. 2018;37(5):537-547.
    1. Colvin MM, Cook JL, Chang PP, et al. Sensitization in heart transplantation: emerging knowledge: a Scientific Statement From the American Heart Association. Circulation. 2015;131(18):1608-1639.
    1. Svobodova E, Gazdic T, Kubanek M, et al. Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance. Transpl Int. 2016;29(1):63-72.
    1. Topilsky Y, Gandhi MJ, Hasin T, et al. Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy: a three-dimensional volumetric intravascular ultrasound study. Transplantation. 2013;95(2):389-396.
    1. Coutance G, d’Orio V, Belin L, et al. Favorable outcome of an exclusively posttransplant prophylactic strategy after heart transplantation in recipients with high immunological risk. Transplantation. 2019;103(7):1439-1449.
    1. Clerkin KJ, Farr MA, Restaino SW, et al. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. J Heart Lung Transplant. 2017;36(5):540-545. Published online November 17, 2016.
    1. Raess M, Fröhlich G, Roos M, et al. Donor-specific anti-HLA antibodies detected by Luminex: predictive for short-term but not long-term survival after heart transplantation. Transpl Int. 2013;26(11):1097-1107.
    1. Kransdorf EP, Kittleson MM, Patel JK, Pando MJ, Steidley DE, Kobashigawa JA. Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. J Heart Lung Transplant. 2017;36(7):787-796.
    1. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report-2018; Focus Theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1155-1168.
    1. Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report-2013; focus theme: age. J Heart Lung Transplant. 2013;32(10):951-964.
    1. Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017;36(10):1080-1086.
    1. Chih S, Patel J. Desensitization strategies in adult heart transplantation-Will persistence pay off? J Heart Lung Transplant. 2016;35(8):962-972.
    1. Bucin D, Johansson S, Malm T, et al. Heart transplantation across the antibodies against HLA and ABO. Transpl Int. 2006;19(3):239-244.
    1. Lefaucheur C, Loupy A. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018;379(26):2580-2582.
    1. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11(11):2405-2413.
    1. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233-1243.
    1. Hillmen P, Hall C, Marsh JCW, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552-559.
    1. Valenzuela NM, Askar M, Heidt S, et al. Minimal data reporting standards for serological testing for histocompatibility. Hum Immunol. 2018;79(12):865-868.
    1. Zhang X, Reinsmoen NL. Comprehensive assessment for serum treatment for single antigen test for detection of HLA antibodies. Hum Immunol. 2017;78(11-12):699-703.
    1. Reinsmoen NL, Patel J, Mirocha J, et al. Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. J Heart Lung Transplant. 2016;35(2):165-172.
    1. Costanzo MR, Crespo-Leiro MG, Dipchand A, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-956.
    1. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32(12):1147-1162.
    1. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710-1720.
    1. Mehra MR, Dipchand A, Ensminger SM, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29(7):717-727.
    1. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28(5):417-422.
    1. Kfoury AG, Snow GL, Budge D, et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2012;31(1):46-51.
    1. Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant. 2015;15(5):1293-1302.
    1. Loupy A, Lefaucheur C. Antibody-mediated rejection of solid organ allografts. N Engl J Med. 2018;379(12):1150-1160. In Press.
    1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280(14):735-739.
    1. Hirohashi T, Uehara S, Chase CM, et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant. 2010;10(3):510-517.
    1. Badders JL, Jones JA, Jeresano ME, Schillinger KP, Jackson AM. Variable HLA expression on deceased donor lymphocytes: not all crossmatches are created equal. Hum Immunol. 2015;76(11):795-800.
    1. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6(6):1377-1386.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren